Building lasting partnerships that shape the future of human health

Accelagen’s commitment to the industry is grounded in building lasting partnerships and transparent relationships. Unlike many contract research organisations (CROs), our projects are not a transaction. Instead, our experts work with you in true collaboration, supporting you along the entire journey from concept through to commercialisation.

Our world-leading, specialist team deliver end-to-end services focused on holistic strategies throughout all stages of the product lifecycle. We support all organisations in the biotech and pharmaceutical industries across Asia-Pacific, North America and Europe, regardless of your corporate size or stage in your product’s evolution.

We always look to innovate and improve and never settle for the status quo. In an ever-evolving, ever-changing industry, when you are working with Accelagen you are assured of one constant: our commitment to your success with a relentless focus on accelerating the future of human health.

Our case studies

View all case studies

Accelagen leads clinical trial for mRNA COVID-19 vaccine designed for immunosuppressed patients

Innovative biotech HelixNano has partnered with Accelagen to test the next generation of mRNA vaccines.

Accelagen Fast Tracks First-in-Human Anti-BKV Therapy Trial

When Swiss biotech sponsor Memo Therapeutics sought to trial a promising novel treatment for BK virus (Human polyomavirus 1), they turned to Accelagen.

Collaborating with Griffith University on a world-first clinical trial in the treatment of spinal cord injuries

Accelagen partners with Griffith University on a world-first trial using olfactory cells to treat spinal cord injuries and restore nerve function.

Negative to Positive: How Accelagen turned a double rejection into a successful medical technology ready to market

Accelagen secured ethics approval in 42 days for a US medical device company after two rejections through strategic regulatory expertise.

Australians benefit from first-ever cancer trial

Accelagen partners with ImaginAb for groundbreaking CD8 ImmunoPET cancer trials, offering non-invasive alternatives to tissue biopsies for immunotherapy patient

Clinical Development

Regulatory affairs

Building lasting partnerships that shape the future of human health

Our case studies

Accelagen leads clinical trial for mRNA COVID-19 vaccine designed for immunosuppressed patients

Accelagen Fast Tracks First-in-Human Anti-BKV Therapy Trial

Collaborating with Griffith University on a world-first clinical trial in the treatment of spinal cord injuries

Negative to Positive: How Accelagen turned a double rejection into a successful medical technology ready to market

Australians benefit from first-ever cancer trial

Leading the way

Device Approvals

Category 1 Applications

ODD Submissions

TGA Meetings

IND/IDE Submissions

CTN Submissions

Clinical Trial Sites